In an interview on the first-in-human phase 1 study of gintemetostat, Saad Z. Usmani, MD, PhD, detailed the initial safety ...
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company ...
Company to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American Association for Cancer ...
DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the ...
Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...
Initiation of the IIMPACT study follows promising Phase 1 results where Restem-L demonstrated clinically meaningful efficacy ...
ETD001 is well tolerated in healthy individuals at higher doses than predicted to be therapeutic for long-lasting enhancement of mucociliary clearance Results showed excellent consistency between ...